Krystal Biotech, Inc. (KRYS)
311.50
-8.63
(-2.70%)
USD |
NASDAQ |
Oct 23, 16:00
311.49
-0.01
(0.00%)
After-Hours: 20:00
Krystal Biotech Enterprise Value : 8.382B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 8.382B |
| October 22, 2026 | 8.638B |
| October 21, 2026 | 8.698B |
| October 20, 2026 | 8.794B |
| October 19, 2026 | 8.641B |
| October 16, 2026 | 8.533B |
| October 15, 2026 | 8.930B |
| October 14, 2026 | 8.950B |
| October 13, 2026 | 8.668B |
| October 12, 2026 | 8.991B |
| October 09, 2026 | 8.978B |
| October 08, 2026 | 8.850B |
| October 07, 2026 | 8.769B |
| October 06, 2026 | 8.835B |
| October 05, 2026 | 9.073B |
| October 02, 2026 | 8.701B |
| October 01, 2026 | 8.791B |
| September 30, 2026 | 9.006B |
| September 29, 2026 | 9.080B |
| September 28, 2026 | 9.139B |
| September 25, 2026 | 9.398B |
| September 24, 2026 | 9.373B |
| September 23, 2026 | 9.278B |
| September 22, 2026 | 9.548B |
| September 21, 2026 | 9.044B |
| Date | Value |
|---|---|
| September 18, 2026 | 9.127B |
| September 17, 2026 | 9.189B |
| September 16, 2026 | 9.127B |
| September 15, 2026 | 9.128B |
| September 14, 2026 | 9.227B |
| September 11, 2026 | 9.433B |
| September 10, 2026 | 9.390B |
| September 09, 2026 | 9.465B |
| September 08, 2026 | 9.559B |
| September 04, 2026 | 9.766B |
| September 03, 2026 | 10.16B |
| September 02, 2026 | 10.09B |
| September 01, 2026 | 9.931B |
| August 31, 2026 | 9.799B |
| August 28, 2026 | 9.565B |
| August 27, 2026 | 9.743B |
| August 26, 2026 | 9.811B |
| August 25, 2026 | 9.705B |
| August 24, 2026 | 9.277B |
| August 21, 2026 | 9.421B |
| August 20, 2026 | 9.138B |
| August 19, 2026 | 9.325B |
| August 18, 2026 | 9.013B |
| August 17, 2026 | 9.099B |
| August 14, 2026 | 8.997B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| TG Therapeutics, Inc. | 8.494B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Cytokinetics, Inc. | 8.598B |
| Ionis Pharmaceuticals, Inc. | 7.245B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 54.77M |
| Revenue (Quarterly) | 119.22M |
| Total Expenses (Quarterly) | 64.45M |
| EPS Diluted (Quarterly) | 1.786 |
| Gross Profit Margin (Quarterly) | 93.46% |
| Profit Margin (Quarterly) | 45.94% |
| Earnings Yield | 2.56% |
| Operating Earnings Yield | 2.09% |
| Normalized Earnings Yield | 2.562 |